Investment in pneumonia and pneumococcal research
- PMID: 25444398
- PMCID: PMC6995355
- DOI: 10.1016/S1473-3099(14)70949-1
Investment in pneumonia and pneumococcal research
Figures
Comment in
-
Investment in antibiotics against pneumonia.Lancet Infect Dis. 2015 Apr;15(4):376. doi: 10.1016/S1473-3099(15)70057-5. Lancet Infect Dis. 2015. PMID: 25809890 No abstract available.
-
Challenges in mapping research investments for treatments against pneumonia.Lancet Infect Dis. 2015 Nov;15(11):1262. doi: 10.1016/S1473-3099(15)00351-5. Lancet Infect Dis. 2015. PMID: 26531036 No abstract available.
References
-
- Murray CJ, Vos T, Lozano R, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2197–223. - PubMed
-
- Head MG, Fitchett JR, Cooke MK, Wurie FB, Hayward AC, Atun R. UK investments in global infectious disease research 1997–2010: a case study. Lancet Infect Dis. 2013;13:55–64. - PubMed
-
- Centers for Disease Control and Prevention. Threat Report 2013. Antibiotic resistance threats. [accessed Oct 14, 2013];2013 http://www.cdc.gov/drugresistance/threat-report-2013/
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
